Difference between revisions of "Ropeginterferon alfa-2b (Besremi)"
m |
m |
||
Line 6: | Line 6: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Polycythemia vera]] | *[[Polycythemia vera]] | ||
− | + | ==History of changes in FDA indication== | |
− | + | *2021-11-12: Initial approval for adults with [[polycythemia vera]]. ''(Based on PEGINVERA)'' | |
− | |||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*2019-02-15: Initial authorization | *2019-02-15: Initial authorization | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' AOP2014 | *'''Code name:''' AOP2014 | ||
+ | *'''Generic name:''' ropeginterferon alfa-2b-njft | ||
*'''Brand name:''' Besremi | *'''Brand name:''' Besremi | ||
Line 23: | Line 23: | ||
[[Category:EMA approved in 2019]] | [[Category:EMA approved in 2019]] | ||
+ | [[Category:FDA approved in 2021]] |
Revision as of 23:14, 27 May 2023
General information
Class/mechanism per NCI Drug Dictionary: A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b) protein, in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon subcutaneous administration, IFN-a2b binds to specific interferon cell-surface receptors. This activates interferon-mediated signal transduction pathways and induces the transcription and translation of genes with interferon-specific response elements (ISREs); the protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a predominant (90%) positional isomer which allows for further increases in stability and a longer half-life than previous PEG conjugates.
Route: SC
Extravasation: n/a
Diseases for which it is used
History of changes in FDA indication
- 2021-11-12: Initial approval for adults with polycythemia vera. (Based on PEGINVERA)
History of changes in EMA indication
- 2019-02-15: Initial authorization
Also known as
- Code name: AOP2014
- Generic name: ropeginterferon alfa-2b-njft
- Brand name: Besremi